FDA Inspection
Boehringer Ingelheim Fremont, Inc.Boehringer Ingelheim Fremont, Inc. – FDA Inspection, Nov 4, 2022
Record Details
This FDA Inspection record concerns Boehringer Ingelheim Fremont, Inc., with an inspection on November 4, 2022, issued by the Center for Drug Evaluation and Research, covering drugs.
- Inspection Date
- November 4, 2022
- Product Type
- Drugs
View Company Profile
ID · 817f2419-ae3e-4fdf-b387-b7551f09fb7e
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1187410
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
FDA Citations
1- 21 CFR 211.22(d)Procedures not in writing, fully followed
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Boehringer Ingelheim Fremont, Inc.
7| Date | Classification | Office | Project area |
|---|---|---|---|
| May 16, 2024 | Not classified | San Francisco District Office | |
| April 13, 2023 | Not classified | San Francisco District Office | |
| August 24, 2018 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| April 4, 2017 | Not classified | San Francisco District Office | |
| May 28, 2014 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Boehringer Ingelheim Fremont, Inc.
- FDA Inspection 1263388 - 2024-05-16
- FDA Inspection 1205076 - 2023-04-13
- FDA Inspection 1063730 - 2018-08-24
- FDA Inspection 1005958 - 2017-04-04
- FDA Inspection 882791 - 2014-05-28
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.